For research use only
| Cat No. | ABC-TC504S |
| Product Type | Human Breast Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Breast Cancer |
| Product Code | JIMT1; JIMT |
JIMT-1 cells are HER2-positive, drug-resistant human breast cancer cells lacking hormone receptors, ideal models for HER2 resistance and targeted therapy.
JIMT-1 is a human breast cancer cell line derived from the pleural effusion of a 62-year-old female patient with ductal breast carcinoma. The cells are of epithelial progenitor cell origin and exhibit HER-2 gene amplification, leading to high expression of HER-2 mRNA and protein. These cells are resistant to HER-2-targeting drugs and lack estrogen and progesterone receptors, making them a valuable model for studying HER-2-related drug resistance. JIMT-1 cells grow as an adherent monolayer in DMEM medium supplemented with 10% fetal bovine serum, with the ability to form xenograft tumors in mice. This cell line does not show any specific viral infections (e.g., HPV, HIV, or EBV), but its HER-2 antibody resistance is a key characteristic.
| Product Code | JIMT1; JIMT |
| Species | Human |
| Cat.No | ABC-TC504S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Breast Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
JIMT-1 breast cancer cell line offers crucial roles in cancer research and drug development. It can generate xenograft tumors in mice models, allowing researchers to evaluate drug efficacy and inhibitor effectiveness both in vitro and in vivo. For instance, JIMT-1 cells have been extensively used to test HER-2-targeting drugs and small molecule tyrosine kinase inhibitors designed to block the HER-2 signaling pathway. Additionally, JIMT-1 is a HER-2-positive but trastuzumab-resistant cell line, making it particularly useful for studying resistance mechanisms. These applications make JIMT-1 a valuable tool for understanding breast cancer biology, investigating mechanisms of therapeutic resistance, and developing targeted therapies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
JIMT-1 cell line doubling time is 30-40h, and it is recommended to change medium every 2-3 days.
JIMT-1 cells overexpress HER-2 mRNA and are insensitive to drugs that inhibit HER-2 (such as trastuzumab). JIMT-1 cells have an amplified HER-2 oncogene, which showed no identifiable mutations in its coding sequence.
The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin.
The recommended cell density for JIMT-1 cells before passage is 1-2 × 10^5 cells/mL. We recommend to use a T-25 setup at a dilution of 1:5-1:10 (our cell count is approximately 1-2M/vial).
